Here are sales figures for the third quarter for top-selling Pfizer prescription drugs:

PRODUCT NAME MAIN CONDITION/USE 3Q 2011 SALES 3Q 2010 SALES PERCENT CHANGE

Lipitor High cholesterol $2.6 billion $2.53 billion up 3 percent

Prevnar 13 Pneumococcal vaccine $1.01 billion $735 million up 37 percent

Enbrel (outside U.S.) Rheumatoid arthritis $957 million $799 million up 20 percent

Lyrica Fibromyalgia/pain $961 million $757 million up 27 percent

Celebrex Pain $643 million $578 million up 11 percent

Viagra Erectile dysfunction $493 million $459 million up 7 percent

Norvasc High blood pressure $350 million $330 million up 6 percent

Zyvox MRSA infections $321 million $285 million up 13 percent

Xalatan Glaucoma $277 million $416 million down 33 percent

Sutent Multiple cancers $298 million $257 million up 16 percent

___

Note: Sales changes include favorable benefit from currency exchange rates.

Source: Pfizer Inc.